 |
After participating
in this activity, participants should be able to:
Discuss the prevalence of chronic kidney disease (CKD) in the US
population and suboptimal treatment of anemia;
Summarize
the advances made in defining the stages of CKD and describe current
guidelines for anemia correction;
Describe the
effects of the correction of anemia on cardiorenal function in patients
with congestive heart failure (CHF): and
Summarize
knowledge about treatment plans and models of care that are directed
at improving CKD treatment and limiting progression of disease.
 |
John
Dickmeyer, M.D.
Senior Vice President
RMS Disease Management, Inc.
Lafayette, CA, USA
Paul Kimmel, M.D.
Professor of Medicine
George Washington University
Medical Center
Washington, DC, USA
William
McClellan, M.D., MPH
Clinical Professor of Medicine
Emory University
School of Medicine
Atlanta, GA, USA
Robert
Provenzano, M.D., FACP
Chair, Department of Nephrology
St. John Hospital and Medical Center
Detroit, MI, USA
Donald
Silverberg, M.D.
Department of Nephrology
Tel Aviv Medical Center
Department of Nephrology
Tel Aviv, Israel
Ajay Singh, M.B., M.R.C.P.
Associate Professor of Medicine
Harvard Medical School
Boston, MA, USA |
|
 |
|
|
Post-test and evaluation form are at
this link, but you must listen to all talks from
this symposium prior to completing the test.
|
|
CME: The University of Minnesota is accredited by the Accreditation
Council for Continuing Medical Education (AACME) to sponsor continuing medical education
for physicians.
The
University of Minnesota designates this educational
activity for up to 1.5 hours in category 1 credit
towards the AMA Physician's Recognition Award. Each physician
should claim only those hours of credit actually spent
in the educational activity.
CEU: These talks are also designated to provide 1.5 hours of CEU Nursing Education credits, sponsored
by the Renal Education Association. The Renal Education Association is accredited by
the State of California Board of Nursing to provide continuing education for nurses
(Provider number: CEP 13092).
Posting date: January 15, 2002.
Review date: January 15, 2003 |
|
INSTRUCTIONS FOR CREDIT : |
Participation
in this self-study activity should be completed in approximately
two (1.5) hours. There are no fees for participating and receiving
CME or CEU credit for this activity. To successfully complete this
activity and receive credit, participants must follow these
steps during the period January 15, 2002 through January 15, 2003.
1. Register for continuing education credit by completing the
registration process.
2. Read the goals and learning objectives.
3. Read the article text and tables, and review figures.
4. Read, complete, and submit answers to the post test questions
and evaluation questions. You must receive a test score of at
least 75% and respond to all evaluation questions to receive
your online CME or CEU certificate.
The
primary target audience is physicians involved in the care of renal patients (CME), and nephrology nurses,
dialysis technicians and pharmacists (CEU).
|
FACULTY
DISCLOSURE STATEMENTS : |
All
faculty participating in continuing medical education programs
are expected to disclose to the program audience any real or
apparent conflict of interest related to the subject under discussion.
The faculty disclosure information is as follows:
Dickmeyer, John: Stocks (directly purchases): RMS Disease Management
Kimmel, Paul: No potential conflicts of interest.
McClellan:
Other financial or material support: Ortho Biotech Products, L.P.: Early Renal Insufficiency Advisory Group
Provenzano,
Robert: Consultant, Ortho Biotech; Advisory Board, Amgen
Singh,
Ajay: Consultant to: Ortho Biotech, Amgen, Pfizer, Merck, Pharmacia, Genzyme;
Research Support: Amgen, Ortho Biotech
Silverberg,
Donald: Consultantships: Amgen, Johnson and Johnson
|
DISCLOSURE OF UNLABELED USE: |
This
educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by FDA.
The University of Minnesota, ASN, HDCN and the Renal Education Association do not recommend the
use of any agent outside of the labeled indications. Please
refer to the official prescribing information for each product
for discussion of approved indications, contraindications and
warnings.
|
|
